Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results
SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a…
News
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO
– David Bench resigning to pursue a new career opportunity – NEW YORK, NY, Oct….
Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO
– David Bench resigning to pursue a new career opportunity – NEW YORK, NY, Oct….
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic…
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic…
HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos,…
HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos,…
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD,…
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD,…
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
– Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient…
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
– Updated FemaSeed® LOCAL artificial insemination trial design focuses on male factor infertility in patient…
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to…